Metacrine Inc

Metacrine — Investor Day (September 2021)

85 slides from Metacrine's investor day presentation, Sep 15, 2021

  1. Slide 1: R&D Day September 15, 2021

    R&D Day September 15, 2021 Exhibit 99.1

  2. Slide 2: Legal Disclaimers

    Legal Disclaimers Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development plans, including our plans regarding the potential expa

  3. Slide 3: R&D Day Thought Leaders

    R&D Day Thought Leaders Dr. Juan Pablo Frias E-=MM * Medical Director (Past CMO/CEO), National Research Institute (Los Angeles) + Prior CMO roles at Tethys Bioscience, Johnson & Johnson Wf + Endocrinology, UCSD Jesus Rivera-Nieves + Professor of Medicine/Gastroenterology, UCSD + Howard Hughes Fellow

  4. Slide 4: Today's Agenda

    Today’s Agenda 12:00pm (ET) - 12:15pm (ET) We oO T) — 12:45pm (ET) 0 ination Therapies Dr. Juan Pablo Frias, NRI :! = 1:25pm (ET) The Case for FXR Agonists in IBD Dr. Jesus Rivera-Nieves, UCSD 4:25pm (ET) — 1:35pm (ET) Second Q&A Session 12:45pm (ET) - 12:55pm (ET) First Q&A Session 1:55pm (ET} Fina

  5. Slide 5: Our Story

    Our Story Potential best-in-class FXR platform from unique chemical scaffold Large therapeutic areas (NASH and IBD) and clini Demonstrated POC in NASH with near-term data readouts Well-capitalized to complete NASH Phase 2a trials and i ite two new trials

  6. Slide 6: Our Pipeline

    Our Pipeline — (monotherapy) METe42 (monotherapy) HSD17p13 inhibitors 9/642 (monotherapy)

  7. Slide 7: Strong Execution in 2021

    Strong Execution in 2021 Granted FDA fast track designation for MET642 program Achieved full enrollment ahead of schedule for MET409 Phase 2a combination trial in patients with Type 2 Diabetes (T2D) and NASH Accomplished full enrollment on schedule for MET642 Phase 2a monotherapy trial in patients w

  8. Slide 8: Key Future Milestones

    Key Future Milestones 2021 2022 121 2H21 1422 2H22 "lan tar) MET409 Phases ASH Ea ‘Spine (m) MET642 sn sai (8) MET409/ —— 642

  9. Slide 9: We Are Bringing Something New to NASH and IBD

    We Are Bringing Something New to NASH and IBD Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767767/ CDC - https://www.cdc.gov/mmwr/volumes/65/wr/mm6542a3.htm#:~:text=In%202015%2C%20a

  10. Slide 10: Accomplished Leadership Team and Experienced Drug Developers

    Accomplished Leadership Team and Experienced Drug Developers 10

  11. Slide 11: Today's Cornerstones

    11 Today’s Cornerstones Significant value for combination treatments in patients with NASH and T2D Significant overlap of NASH and T2D patients in U.S highlights overwhelming need for new combination approaches Strong rationale for FXR-based therapies in IBD FXR agonism impacts multiple mechanisms o

  12. Slide 12: Treatment Combination Strategies in Patients with Type 2 Diabetes and NAFLD

    Juan Pablo Frías, M.D. Medical Director and Principal Investigator, National Research Institute, Los Angeles, CA Treatment Combination Strategies in Patients with Type 2 Diabetes and NAFLD

  13. Slide 13: Disclosures

    Disclosures Research Support: Akero, AbbVie, AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, Intercept, IONIS, Janssen, Madrigal, Metacrine, Merck, NorthSea Therapeutics, Novartis, Novo Nordisk, Oramed, Pfizer, Poxel, Sanofi, Theracos Advisory Boards and Consulting: Akero, Altimmune, Axcella Heal

  14. Slide 14: NAFLD: Definitions and clinical significance

    NAFLD: Definitions and clinical significance Chalasani N, et al. Hepatology. 2018;67:328-357. EASL-EASD-EASO. J Hepatol. 2016;64:1388-1402. Younossi ZM, et al. Hepatology. 2016;64:73-84. Fatty Liver Disease ≥5% hepatic steatosis In the US: 3rd leading cause of cirrhosis 2nd most common indication fo

  15. Slide 15: Estimated global prevalence of NAFLD: 25%

    Estimated global prevalence of NAFLD: 25% Younossi ZM, et al. Hepatology. 2016;64:73-84. Meta-analysis: NAFLD diagnosed by imaging (US, CT, MRI/SPECT; n=45 studies). 24% 31% 24% 13% 32% 27% Prevalence increases with age: 34% in people 70-79 years of age 15

  16. Slide 16: Prevalence of NAFLD among patients with Type 2 Diabetes

    Prevalence of NAFLD among patients with Type 2 Diabetes (T2D) NAFLD diagnosed by ultrasound or H-MRS. Data displayed as prevalence (95% CI). NAFLD, non-alcoholic fatty disease; NASH, non-alcoholic steatohepatitis; T2D, type 2 diabetes. Younossi ZM, et al. J Hepatol. 2019; 71(4):793-801. 16

  17. Slide 17: Importance of NAFLD/NASH in T2D

    Importance of NAFLD/NASH in T2D Patients with T2D are particularly susceptible to more severe forms of NAFLD1,2 and have a higher progression to HCC3 NAFLD may be present in up to 70% of patients with diabetes2 NASH (biopsy-proven) may be found in up to 20% of patients with T2D2 Advanced fibrosis ma

  18. Slide 18: Moderate to severe fibrosis affects one in six patients with T2D

    Moderate to severe fibrosis affects at least one out of six (15%) patients with T2D Lomonaco R, et al. Diabetes Care. 2021;44:399-406. 18

  19. Slide 19: ADA guidelines support screening for fibrosis in T2D

    “These results support the American Diabetes Association guidelines to screen for clinically significant fibrosis in T2D patients with steatosis or elevated ALT.” 19 Moderate to severe fibrosis affects at least one out of six (15%) patients with T2D

  20. Slide 20: Cusi K. Diabetes Care 2020

    Cusi K. Diabetes Care 2020:43;275-279 20

  21. Slide 21: 2021 ADA: glucose-lowering medication in T2D

    2021 ADA: glucose-lowering medication in T2D NO If A1C above individualised target proceed as below Consider independently of baseline A1C, individualised A1C target, or metformin use* Indicators of high-risk or established ASCVD, CKD, or HF† 1st-line therapy is metformin & comprehensive lifestyle (

  22. Slide 22: Therapeutic modalities that intersect treatment of T2D and NAFLD

    Therapeutic modalities that intersect the treatment of T2D and NAFLD Weight loss Thiazolidinediones (pioglitazone) GLP-1 receptor agonists SGLT-2 inhibitors Unimolecular multiagonists (GLP-1/GIP, GLP-1/glucagon receptor, GLP-1/GIP/glucagon receptor) Note: There are no currently approved pharmacologi

  23. Slide 23: Weight loss improves NASH and fibrosis but is difficult to maintain

    Weight loss results in significant improvements in NASH and fibrosis, but is difficult to achieve and maintain Vilar-Gomez E et al. Gastroenterology. 2015;149:367–378; Promrat K et al. Hepatology. 2010;51:121–129; Harrison SA et al. Hepatology. 2009;49:80–86; Wong VWS et al. J Hepatol. 2013;59:536–5

  24. Slide 24: Pioglitazone in patients with prediabetes or T2D and NASH

    Pioglitazone in patients with prediabetes or T2D and NASH: 18-month outcomes Randomized, placebo-controlled, double-blind phase 4 study of patients with NASH and prediabetes or T2D (n=101) Cusi K, et al. Ann Intern Med. 2016;165:305. 24

  25. Slide 25: GLP-1 RAs have multifactorial effects

    GLP-1 RAs have multifactorial effects *Fasting and postprandial lipids. CV, cardiovascular; GLP-1, glucagon-like peptide-1. Campbell JE and Drucker DJ. Cell Metab. 2013;17:819–837; Tong J and D'Alessio D. Diabetes. 2014;63:407–409; Hogan AE et al. Diabetologia. 2014;57:781–784; Hermansen K et al. Di

  26. Slide 26: Efficacy and safety of semaglutide vs placebo in NASH

    Efficacy and safety of semaglutide vs placebo in patients with NASH (Phase 2 semaglutide trial) 26 Key Eligibility Criteria: 18-75 years old, biopsy-proven NASH, BMI 25-45 kg/m2, A1C <9.0% if T2D Primary Endpoint: NASH resolution without worsening of fibrosis at week 72 Liver biopsy at baseline and

  27. Slide 27: SGLT-2 inhibitors have pleiotropic effects

    SGLT-2 inhibitors have pleotropic effects and are recommended as first or second-line therapy for T2D Wanner and Marx (2018) Diabetologia DOI 10.1007/s00125-018-4678-z 27

  28. Slide 28: Empagliflozin associated with improvements in liver enzymes

    Empagliflozin associated with improvements in liver enzymes In analyses from 3 large datasets, including the EMPA-REG OUTCOME trial, empagliflozin consistently lowered ALT and AST concentrations Reductions in ALT were consistently greater than reductions in AST, and were more prominent in patients w

  29. Slide 29: Kahl S, et al. Diabetes Care 2020

    29 Kahl S, et al. Diabetes Care. 2020;43:298-305 29

  30. Slide 30: Empagliflozin in patients with NAFLD

    Empagliflozin in patients with NAFLD E-LIFT: 20-week, randomized, open-label study of empagliflozin vs. standard diabetes treatment in patients with T2D and NAFLD (n=42)1 Kuchay, et al. Diabetes Care. 2018;41:1801 30

  31. Slide 31: Peptide-based multi-agonists: A new paradigm in metabolic pharmacology

    Peptide‐based multi‐agonists: A new paradigm in metabolic pharmacology Journal of Internal Medicine, Volume: 284, Issue: 6, Pages: 581-602, First published: 19 September 2018, DOI: (10.1111/joim.12837) 31

  32. Slide 32: Tirzepatide development program includes weight loss and NASH trials

    Tirzepatide development program includes weight loss and NASH trials 32

  33. Slide 33: Bril F, Cusi K. Diabetes Care 2017

    Bril F, Cusi K. Diabetes Care 2017;40:419-430 33

  34. Slide 34: NASH and T2D: A population likely requiring combination approaches

    NASH and T2D: A population likely requiring multiple combinatorial approaches to address patient/physician needs Each specialty likely has its own preferences for specific attributes in a combination product 34

  35. Slide 35: FXR agonist: A potential front-line therapy for NASH

    FXR agonist: A potential front-line therapy for NASH Balanced FXR activation in both the liver and intestine delivers the optimal profile Fibrosis improvement demonstrated in large clinical trials(1) is best predictor of long-term patient outcomes 35 FLINT and REGENERATE clinical trials

  36. Slide 36: FXR agonist and SGLT-2 inhibitor combination therapy for NASH with T2D

    FXR agonist and SGLT-2 inhibitor combination therapy to address significant unmet needs in NASH patients with T2D 1Younossi ZM, et al. Diabetes Care 2020:43:283-289. 2Perumpail BJ, et al. World J Gastroenterol, 2017: 23:8263-8276.;Younossi ZM, et al. Diabetes Care, 2020:43:283-289. 3Kuchay MS, et al

  37. Slide 37: Phase 2a combination trial with MET409 and empagliflozin

    Phase 2a combination trial with MET409 and empagliflozin in NASH patients with T2D Topline Data in 4Q21 37

  38. Slide 38: Summary and conclusion

    Summary and conclusion NAFLD is very common in patients with type 2 diabetes and is more severe and progressive in this patient population GLP-1 RAs and SGLT2i are first or second-line treatments for T2D due to their glycemic and extra-glycemic benefits, including proven cardiorenal protective effec

  39. Slide 39: Thank you

    Thank you

  40. Slide 40: Metacrine

    @ )METACRINE

  41. Slide 41: FXR Agonism in the Treatment of Inflammatory Bowel Disease (IBD)

    FXR Agonism in the Treatment of Inflammatory Bowel Disease (IBD) Jesus Rivera-Nieves, M.D. Professor of Medicine/Gastroenterology

  42. Slide 42: IBD Is a Challenging Disease

    ~3 million patients in US afflicted with IBD Significant reduction in quality of life including pain and psychosocial impact Co-morbid illnesses beyond the intestine Despite availability of multiple, approved therapies, clear unmet needs exist Most advanced therapies are parenteral In trials, clinic

  43. Slide 43: Rationale for FXR-Based Therapy in IBD

    In addition to liver-specific activity, FXR is highly expressed by intestinal epithelial cells and plays a key role in healthy intestinal function Intestinal FXR actions maintain epithelial barrier and regulate innate immune response Preserves physical integrity and function of epithelial barrier Re

  44. Slide 44: FXR Plays a Protective Role in IBD Pathology

    References: (1) Vavassori et al. (2009) J Immunol (2) Wilson et al. (2020) Scientific Reports 44 FXR Plays a Protective Role in IBD Pathology Loss of Function Worsens Disease Severity

  45. Slide 45: Small Molecule FXR Agonists Improve Colitis in Preclinical IBD Models

    References: (1) Gadaleta et al., (2011) Gut (2) Liu et al., (2018) DDW: S198-99 45 Small Molecule FXR Agonists Improve Colitis in Preclinical IBD Models *OCA = obeticholic acid = INT-747

  46. Slide 46: FXR Agonism Impacts Multiple Mechanisms of IBD Pathogenesis

    46 FXR Agonism Impacts Multiple Mechanisms of IBD Pathogenesis

  47. Slide 47: FXR Agonism Protects Epithelial Barrier Integrity and Function

    References: (1) Gadaletta et al., (2011) Gut (2) Metacrine Data on File 47 FXR Agonism Protects Epithelial Barrier Integrity and Function

  48. Slide 48: FXR Agonism Exerts Direct Anti-Bacterial Effects at Intestinal Lining

    References: (1) Ubeda et al., 2016, J Hepa (2) Liu et al., (2019) DDW: S382 (3) Metacrine Data on File 48 FXR Agonism Exerts Direct Anti-Bacterial Effects at Intestinal Lining

  49. Slide 49: FXR Agonism Lowers Key IBD-Associated Cytokine Expression

    Reference: (1) Vavassori 2009 J Immunol (2) Liu et al., (2021) DDW:S236 49 FXR Agonism Lowers Key IBD-Associated Cytokine Expression

  50. Slide 50: FXR Agonism Regulates Innate Immune Cells

    Reference: Liu et al., (2021) DDW:S236 50 FXR Agonism Regulates Innate Immune Cells

  51. Slide 51: FXR Agonists Have the Potential to Be Combined with Existing Therapies

    References: (1) Liu et al., (2020) C&C Congress: S11 (2) Liu et al., (2021) DDW:S236 Means ± SEM; All treatments are in therapeutic mode, * p<0.05, **p<0.01 One-Way ANOVA 51 FXR Agonists Have the Potential to Be Combined with Existing Therapies

  52. Slide 52: FXR Benefit Across Multiple Preclinical Models

    FXR Benefit Across Multiple Preclinical Models Strengthens Opportunity for Translation to Clinic 52

  53. Slide 53: Potential for FXR Agonism in IBD Treatment Paradigm

    Potential for FXR Agonism in IBD Treatment Paradigm 53

  54. Slide 54: Potential for FXR Agonism in IBD Treatment Paradigm

    Potential for FXR Agonism in IBD Treatment Paradigm 54

  55. Slide 55: Potential for FXR Agonism in IBD Treatment Paradigm

    Potential for FXR Agonism in IBD Treatment Paradigm 55

  56. Slide 56: FXR Agonism Could Change the Treatment Paradigm

    56 Mechanistic action addresses key IBD pathology Preclinical evidence suggests a strong role in disease management Once-daily, oral drug improves compliance and is preferred to parenteral drugs Unlike biologics, therapy is non-immunogenic and effect will not lessen over time Non-immunosuppressive t

  57. Slide 57: Thank You!

    Thank You! UCSan Diego Heattn Syste

  58. Slide 58: Next Steps: Clinical Proof-of-Concept Trial Design in Ulcerative Colitis

    Next Steps: Clinical Proof-of-Concept Trial Design in Ulcerative Colitis 58 Study Objectives Safety & tolerability Demonstrate significant clinical and histologic improvement over 12 weeks of therapy Key Efficacy Endpoints Clinical remission Clinical response Mucosal healing

  59. Slide 59: Metacrine

    @ )METACRINE

  60. Slide 60: HSD17b13 as a therapeutic target for fatty liver disease

    Dr. Stefano Romeo HSD17b13 as a therapeutic target for fatty liver disease

  61. Slide 61: Non-alcoholic steatohepatitis – Mayo Clinic experiences

    Ludwig J Mayo Clin Proc 1980 Non-alcoholic steatohepatitis – Mayo Clinic experiences with a hitherto unnamed disease 61

  62. Slide 62: What it takes to make a blockbuster drug?

    Organ specificity to avoid side effects Human genetic variation robustly associated with protection against a disease Loss of function variants are easier to target Cardiovascular disease (CVD) examples Efficacy of PCSK9 inhibition to lower LDL-cholesterol and reduce CVD Failure of all HDL-cholester

  63. Slide 63: Natural history of fatty liver disease

    Natural history of fatty liver disease S Romeo Cell Met 2020 63

  64. Slide 64: HSD17b13 rs72613567 associates with lower ALT

    Abul-Usn, N Eng J Med 2018 HSD17b13 rs72613567 associates with lower ALT 64

  65. Slide 65: HSD17b13 rs72613567 protects against liver inflammation and fibrosis

    Abul-Usn, N Eng J Med 2018, Ma et al Hepat 2019 HSD17b13 rs72613567 protects against liver inflammation and fibrosis 65

  66. Slide 66: HSD17b13 rs72613567 protects against liver cirrhosis

    Weights are calculated by random effects analyses Wang Eur Rev Med Pharmacol Sci 2020 HSD17b13 rs72613567 protects against liver cirrhosis 66

  67. Slide 67: HSD17b13 rs72613567 protects against hepatocellular carcinoma

    Weights are calculated by random effects analyses Wang Eur Rev Med Pharmacol Sci 2020 HSD17b13 rs72613567 protects against hepatocellular carcinoma 67

  68. Slide 68: HSD17b13 rs72613567 protects against chronic liver disease

    HSD17b13 rs72613567 protects against chronic liver disease 68

  69. Slide 69: Alcoholic and non-alcoholic liver disease share common genetic determinants

    Alcoholic and non-alcoholic liver disease share common genetic determinants 69

  70. Slide 70: Protective effect of HSD17b13 larger in PNPLA3 I148M carriers

    Genetic Epidemiology, First published: 29 June 2021, DOI: (10.1002/gepi.22392) 70 The protective effect of HSD17b13 on liver damage is larger in carriers of the PNPLA3 I148M variant

  71. Slide 71: What it takes to make a blockbuster drug?

    Organ specificity to avoid side effects Human genetic variation robustly associated with protection against a disease Loss of function variants are easier to target 71 What it takes to make a blockbuster drug?

  72. Slide 72: HSD17b13 is highly expressed in the liver

    Protein Atlas (https://www.proteinatlas.org/ENSG00000170509-HSD17B13/tissue) HSD17b13 is highly expressed in the liver 72

  73. Slide 73: What it takes to make a blockbuster drug?

    Organ specificity to avoid side effects Human genetic variation robustly associated with protection against a disease Loss of function variants are easier to target 73 What it takes to make a blockbuster drug?

  74. Slide 74: HSD17b13 rs72613567 results in a splicing site variation

    Abul-Usn, N Eng J Med 2018 HSD17b13 rs72613567 results in a splicing site variation 74

  75. Slide 75: HSD17b13 rs72613567 results in a truncated protein and loss of function

    Abul-Usn, N Eng J Med 2018 75 HSD17b13 rs72613567 results in a truncated protein and loss of function

  76. Slide 76: What it takes to make a blockbuster drug?

    Organ specificity to avoid side effects Human genetic variation robustly associated with protection against a disease Loss of function variants are easier to target 76 What it takes to make a blockbuster drug?

  77. Slide 77: HSD17b13 downregulation in humans reduces ALT levels

    E Gane EASL meeting 2021 HSD17b13 downregulation in humans reduces ALT levels 77 NTC04202354 in 5 volunteers with fatty liver Administered RNAi and biopsy after 71 days Well-tolerated by volunteers Average reduction in hepatic HSD17b13 mRNA and protein was > 80% Average reduction in ALT was > 48%

  78. Slide 78: Conclusions

    78 Conclusions HSD17b13 rs72613567 protects against liver disease by inducing a loss of function mutation HSD17b13 is highly expressed in the liver The inhibition of HSD17b13 will be beneficial and specific against liver disease

  79. Slide 79: Thank you!

    Thank you!

  80. Slide 80: HSD17b13 Small Molecule Inhibitors Have Great Potential

    Small molecule HSD17b13 inhibitors have great potential Targets patients with most significant need for medical intervention Combine well with other mechanisms such as FXR agonists Challenges for development of small molecule inhibitors HSD17b13 is part of a large enzyme family – need for selectivit

  81. Slide 81: Recent Development of HSD17b13 Small Molecule Inhibitors

    Recent Development of HSD17b13 Small Molecule Inhibitors 81

  82. Slide 82: Metacrine

    @ )METACRINE

  83. Slide 83: Today's Cornerstones

    83 Today’s Cornerstones Significant value for combination treatments in patients with NASH and T2D Significant overlap of NASH and T2D patients in U.S highlights overwhelming need for new combination approaches Strong rationale for FXR-based therapies in IBD FXR agonism impacts multiple mechanisms o

  84. Slide 84: Next Steps for Metacrine

    Next Steps for Metacrine MET642 2021 2022 41H21 2H21 1H22 2H22 "lone sata) MET409 Prose 2 nASH Taplin gat mee) MET409/ 642 HSD17513 Inhibitor | snr aa tre) | amps eoe

  85. Slide 85: Metacrine

    @ )METACRINE

Metacrine — Investor Day (September 2021) on 6ix